Answers are grounded in this paper and cite their sources.
Among patients with previously treated advanced hepatocellular carcinoma, treatment with cabozantinib resulted in longer overall survival and progression-free survival than placebo. The rate of high-grade adverse events in the cabozantinib group was approximately twice that observed in the placebo group. (Funded by Exelixis; CELESTIAL ClinicalTrials.gov number, NCT01908426 .).
No takes yet. Share an insight, caveat, or question.
Abou‐Alfa et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: